Literature DB >> 7955775

Enhancement of drug absorption by antacids. An unrecognised drug interaction.

P J Neuvonen1, K T Kivistö.   

Abstract

Antacids are widely used for many disorders. The potential of antacids to interact with other concomitantly ingested drugs is well recognised. These interactions usually result in reduced or delayed absorption of the affected drug. However, this is not always the case. In contrast to aluminium hydroxide, magnesium hydroxide and sodium bicarbonate can enhance the absorption of some drugs. For example, magnesium hydroxide can increase the rate and sometimes even the extent of absorption of certain nonsteroidal anti-inflammatory drugs (e.g. tolfenamic acid, mefenamic acid and ibuprofen), sulphonylurea antidiabetic agents [e.g. glipizide, glibenclamide (glyburide) and tolbutamide] and the oral anticoagulant dicoumarol (bishydroxycoumarin). These weakly acidic drugs are nonionised at gastric pH, but are sparingly water soluble. Elevation of the gastric pH by administration of magnesium hydroxide or sodium bicarbonate increases the solubility and absorption of such sparingly water soluble agents. Chelate formation may be involved in the increased absorption of dicoumarol by magnesium hydroxide. In combination antacids containing both aluminium hydroxide and magnesium hydroxide, the absorption enhancing effect of magnesium hydroxide seems to be counterbalanced by the opposing effects of aluminium hydroxide. The clinical significance of increased drug absorption is not clear. However, accelerated and enhanced absorption of analgesic drugs may be beneficial when rapid pain relief is desired. In contrast, an unexpectedly increased hypoglycaemic or anticoagulant effect may be potentially dangerous. Therefore, a knowledge of the potential effect of antacids on the absorption of other drugs is clinically important.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955775     DOI: 10.2165/00003088-199427020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  27 in total

1.  Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Influence of antacids on the bioavailability of glibenclamide.

Authors:  P Zuccaro; R Pacifici; S Pichini; U Avico; G Federzoni; L A Pini; E Sternieri
Journal:  Drugs Exp Clin Res       Date:  1989

3.  The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac.

Authors:  P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Reduction or prevention of aspirin-induced occult gastrointestinal blood loss in man.

Authors:  J R Leonards; G Levy
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

5.  Effect of Mylanta on naproxen bioavailability.

Authors:  S S Weber; A D Bankhurst; E Mroszczak; T L Ding
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

6.  Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids.

Authors:  P J Neuvonen; K T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  The correlation between blood levels of ibuprofen and clinical analgesic response.

Authors:  E M Laska; A Sunshine; I Marrero; N Olson; C Siegel; N McCormick
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

9.  Enhancement of absorption and effect of glipizide by magnesium hydroxide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

Review 10.  Effects of antacids on the clinical pharmacokinetics of drugs. An update.

Authors:  R Gugler; H Allgayer
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

View more
  6 in total

1.  Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs.

Authors:  John Wilton; Elena Kurenova; Laura Pitzonka; Allison Gaudy; Leslie Curtin; Sandra Sexton; William Cance; Gerald Fetterly
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-11-07       Impact factor: 2.441

Review 2.  Enteral drug absorption in patients with short small bowel : a review.

Authors:  René Severijnen; Nazila Bayat; Hans Bakker; Jules Tolboom; Ger Bongaerts
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 4.  Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.

Authors:  Danièle Bentué-Ferrer; Olivier Tribut; Elisabeth Polard; Hervé Allain
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Pharmacology of morphine in obese patients: clinical implications.

Authors:  Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Concomitant prescription of oral fluoroquinolones with an antacid preparation.

Authors:  Ratinder Jhaj; Gurusamy Sivagnanam
Journal:  J Pharmacol Pharmacother       Date:  2013-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.